A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice

Aoki, 1999, Preclinical update on BOTOX® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations, Eur. J. Neurol., 6, S3, 10.1111/j.1468-1331.1999.tb00032.x

Black, 1986, Interaction of 125-I labelled botulinum neurotoxins with nerve terminals— I. Ultrastructural autoradiographic localization and quantitation of distinct membrance acceptors for types A and B on motor nerves, J. Cell Biol., 103, 521, 10.1083/jcb.103.2.521

Brin, 1997, Botulinum toxin: chemistry, pharmacology, toxicity, and immunology, Muscle & Nerve, 20(suppl. 6), S146, 10.1002/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4

Brin, 1999, Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia, Neurology, 53, 1431, 10.1212/WNL.53.7.1431

DasGupta, 1989, The structure of botulinum neurotoxin, 53

Grazko, 1995, Botulinum toxin A for spasticity, muscle spasms, and rigidity, Neurology, 45, 712, 10.1212/WNL.45.4.712

Greene, 1996, Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients, Mov. Disord., 14, 181, 10.1002/mds.870110211

Hughes, 1991, Botulism, 589

Jankovic, 1987, Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study, Neurology, 37, 616, 10.1212/WNL.37.4.616

Jankovic, 1990, Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm, J. Neurol. Neurosurg. Psychiat., 53, 633, 10.1136/jnnp.53.8.633

Jankovic, 1990, Botulinum toxin injections for cervical dystonia, Neurology, 40, 277, 10.1212/WNL.40.2.277

Konig, 1975, Ocular involvement in benign botulism B, Am. J. Ophthalmol., 80, 430, 10.1016/0002-9394(75)90530-9

Lew, 1997, Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia, Neurology, 49, 701, 10.1212/WNL.49.3.701

McLellan, 1996, Therapeutic botulinum type A toxin: factors affecting potency, Toxicon, 34, 975, 10.1016/0041-0101(96)00070-0

Mezaki, 1995, Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study, Neurology, 45, 506, 10.1212/WNL.45.3.506

Nussgens, 1997, Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm, Graefes Arch. Clin. Exp. Ophthalmol., 235, 197, 10.1007/BF00941758

Odergren, 1998, A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia, J. Neurol. Neurosurg. Psychiatry, 64, 6, 10.1136/jnnp.64.1.6

Pearce, 1995, The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin, Toxicon, 33, 217, 10.1016/0041-0101(94)00137-W

Quinn, 1989, Dose standardisation of botulinum toxin, Lancet, 1, 964, 10.1016/S0140-6736(89)92551-8

Scott, 1980, Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery, J. Ped. Ophthalmol. Strab., 17, 21, 10.3928/0191-3913-19800101-06

Sesardic, 1996, Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin, Pharmacol. Toxicol., 78, 283, 10.1111/j.1600-0773.1996.tb01376.x

Simpson, 1981, The origin, structure, and pharmacological activity of botulinum toxin, Pharmacol. Rev., 33, 155

Sloop, 1997, Human response to botulinum toxin injection: type A compared with type B, Neurology, 49, 189, 10.1212/WNL.49.1.189

Sugiyama, 1975, Detection of Clostridium botulinum toxin by local paralysis elicited with intramuscular challenge, Applied Micro., 30, 420, 10.1128/AEM.30.3.420-423.1975

Tsui, 1986, Double-blind study of botulinum toxin in spasmodic torticollis, Lancet, 2, 245, 10.1016/S0140-6736(86)92070-2